In recent years, numerous clinical trials have reported a PCR rate of up to 60% in HER-2-positive breast cancer and triple-negative breast cancer (TNBC), which is far higher than that in luminal breast cancer (Shi et al., 2024; Gianni et al., 2016). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.